Skip to main content
. 2022 May 12;5:449. doi: 10.1038/s42003-022-03376-y

Fig. 4. Psoriatic symptoms are ameliorated by 1,6-β-glucan.

Fig. 4

MIP was induced in Ncf1-deficient mice and in MN + mice (Ncf1*/* mice expressing functional Ncf1 under a human CD68 promotor) with or without co-administration of 1,6-β-glucan (2 mg) and the severity (a) and the prevalence (b) of psoriatic lesions were quantified by macroscopic scoring. The severity (c) and prevalence (d) of psoriatic lesions was followed in Ncf1-deficient mice when 1,6-β-glucan (2 mg) was administered one day after induction of MIP. Development of psoriatic lesions was investigated also in MMR-deficient mice when MIP was induced with or without co-administration of 1,6-β-glucan (2 mg) and when MIP was re-induced by mannan 18 days later (e, f). Number of mice in each group are shown in parentheses. Data are pooled from two (a–d) or one (e, f) experiments. Statistical analyses were performed by Mann–Whitney test to compare the group receiving mannan with the group receiving mannan and β-glucan. *P < 0.05; **P < 0.01. Values are presented as mean and error bars present the SEM.